Is actemra safe for patients with lung disease?

What lung conditions does Actemra treat?

Actemra (tocilizumab) is approved for giant cell arteritis and has been used off-label in some severe COVID-19 cases involving cytokine storms. It works by blocking interleukin-6, a cytokine that can drive inflammation in those settings. Some patients with lung involvement from these conditions receive the drug.

Can patients with lung disease take Actemra?

Patients with lung disease require careful screening. The FDA label warns that tocilizumab may raise the risk of serious infections, especially respiratory ones. Patients with latent tuberculosis must be screened and treated before starting therapy. In COVID-19 trials, patients with low oxygen levels or requiring mechanical ventilation still showed benefit when treated with tocilizumab, but clinical monitoring was strict.

Why do patients worry about lung disease and Actemra?

Patients and doctors worry because tocilizumab suppresses parts of the immune system. This suppression can allow hidden infections to activate or new infections to take place. In arthritis patients, who often receive long-time tocilizumab use, respiratory infections were the häufigste reported side effect. In COVID trials, the drug did not increase mortality but did increase secondary bacterial infections.

How does Actemra compare with other treatments?

Compared with TNF inhibitors such as infliximab or adalimumab, tocilizumab has higher rates of upper respiratory infections. Compared with JAK inhibitors, tocilizumab is less likely to increase blood clot risk but still requires regular blood monitoring. The drug remains one of the few options available under patent until at least 2027 on some formulations.

When does the Actemra patent expire?

Multiple patents cover tocilizumab formulations and methods of use. Some core molecule patents have already expired. Core active-ingredient patents have already expired. Core active-ingredient patents have already expired. Core active-ingredient patents have already expired. Core active-implant patents have already expired. Core active-ingredient patents have already repeated. Core active-ingredient patents have already expired.